Steven Gillis - 10 Jul 2023 Form 4 Insider Report for VBI Vaccines Inc/BC

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 10 Jul 2023
Net transaction value: +$1,004,998
SEC form: 4
Accepted by SEC: 18 Jul 2023, 09:00:21 UTC
Prior SEC filing: 15 Jun 2023
Next SEC filing: 28 Jul 2023
Source filing: View source filing
Reporting owner signature: /s/ Steven Gillis

Key filing fact

Steven Gillis filed Form 4 for VBI Vaccines Inc/BC on 18 Jul 2023.

Key facts

This page summarizes Steven Gillis's Form 4 filing for VBI Vaccines Inc/BC.
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Jul 2023, 09:00.

Change

Previous filing in this sequence was filed on 15 Jun 2023.
Current net transaction value: +$1,004,998.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VBIV transaction

Common Shares, no par value per share

Purchase

Transaction value: $1,004,998
Shares: +609,090
Change %: +140%
Price: $1.65
Shares after: 1,043,292
Date: 10 Jul 2023
Ownership: See Footnotes
Footnotes: F1, F2, F3, F4

VBIV holding

Common Shares, no par value per share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,814
Date: 10 Jul 2023
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VBIV transaction Derivative

Warrant (right to buy)

Purchase

Transaction value
Shares: -609,090
Change %: -50%
Price
Shares after: 609,090
Date: 10 Jul 2023
Ownership: See Footnotes
Underlying class: Common Shares
Underlying amount: 609,090
Exercise price: $1.65
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Includes 100,869 common shares held of record by ARCH Venture Fund VI, L.P. ("ARCH VI") and 942,423 common shares held of record by ARCH Venture Fund X Overage, L.P. (the "ARCH Overage"). ARCH Venture Partners VI, L.P. (the "ARCH GPLP"), as the sole general partner of ARCH VI, may be deemed to beneficially own certain of the shares held of record by ARCH VI. The ARCH GPLP disclaims beneficial ownership of all shares held of record by ARCH VI in which the ARCH GPLP does not have an actual pecuniary interest. ARCH Venture Partners VI, LLC (the "ARCH GPLLC"), as the sole general partner of the ARCH GPLP, may be deemed to beneficially own certain of the shares held of record by ARCH VI. The ARCH GPLLC disclaims beneficial ownership of all shares held of record by ARCH GPLP in which the ARCH GPLLC does not have an actual pecuniary interest.

Footnote F2

ARCH Venture Partners X Overage, L.P. (the "Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own certain of the shares held of record by ARCH Overage. The Overage GPLP disclaims beneficial ownership of all shares held of record by ARCH Overage in which the Overage GPLP does not have an actual pecuniary interest. ARCH Venture Partners X, LLC (the "Overage GPLLC"), as the sole general partner of the Overage GPLP, may be deemed to beneficially own certain of the shares held of record by ARCH Overage. The Overage GPLLC disclaims beneficial ownership of all shares held of record by Overage GPLP in which the Overage GPLLC does not have an actual pecuniary interest.

Footnote F3

The reporting person owns an interest in ARCH GPLP but does not have voting or investment control over the shares held by ARCH VI, and disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The reporting person owns an interest in Overage GPLP and may be deemed to have voting and investment control over the shares held by ARCH Overage as member of the investment committee of Overage GPLLC, but disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

Footnote F4

The 609,090 common shares reported in Table I and accompanying warrants to purchase up to 609,090 common shares reported in Table II of this Form 4 were purchased together at a combined public offering price of $1.65 per share and accompanying warrant, which such combined public offering price included $0.01 per accompanying warrant.